For example, rivastigmine, although initially developed as a dual AChE and BChE inhibitor, has been shown to have a higher affinity for BChE in certain doses, suggesting that at optimal concentrations, it may primarily target BChE in the treatment of AD [7,8]. This evidence concerns the gene BCHE and Alzheimer disease.